Plandai Could Revolutionize Malaria Treatment

The Company is successful in developing a treatment or preventive vehicle for malaria, it could be a very profitable game-changer for the Company given its South Africa plantation and botanical-based therapeutic and go a long way toward cost-effectively eliminating one of the world’s most severe health issues.

Read more...
 
Nuvilex Could Target Breast Cancer in Future Clinical Trial
Nuvilex Inc. (OTCQB – NVLX) could be viewed as a two-headed oncology treatment entity, rather than a firm with a single, proven oncology indication in its arsenal.
Read more...
 
PLPL: An Under-the-Radar Force in Biotechnology
Plandai Biotechnology develops rich highly bioavailable extracts to treat diseases and medical conditions
Read more...
 
NVLX: Further Due Diligence Prompts Higher Target Price

There are 3 reasons why our price target had to be increased by 40% and could be raised even higher in the coming months. 1.New value for breast cancer indication 2.Nanomedicine getting major dollars 3.Firm gearing up for future trials

Read more...
 
Nanomedicine Activity is Major Positive for NVLX

In recent months, a slew of activity has occurred in the nanomedicine, or nanobiotechnology industry, which bodes well for Nuvilex Inc. (OTCQB – NVLX), an international firm engaged in live-cell encapsulation technology to treat pancreatic cancer along with the development and study of the use of medical marijuana for the treatment of oncology patients. 

Read more...
 
Nuvilex Leverages Disparate Expertise to Develop Cannabis-Focused Cancer Treatment

It is not often that a Company that has expertise in two distinct arenas can combine these two disparate groups to develop what could emerge as a unique and ground-breaking cancer treatment method.

Read more...
 
A Cash Generation Machine
For all of you investors out there, we have also published an update on FAB Universal (FU-NYSE). The Company is kicking butt and taking names. Why don’t you own the stock? It has generated $15M in cash and $0.26 in EPS in the last 2 quarters alone, and has a subsidiary that could be worth $7.00 per share on its own down the road. Not bad for a $4 stock, right?
Read more...
 
Inscor Inc. is Poised to Help Relieve Municipal Distress

With few other low-cost solutions to the problem available and only ever-rising costs looming, Inscor (OTCPK – IOGA) has an opportunity to effect real change in government financial management and generate significant revenue for itself in the coming years.

Read more...
 
Health Benefits Down to a “T”

Until the arrival of Plandai Biotechnology, Inc. (OTCQB – PLPL), even many wellness pundits were unaware that substantial increases in bioavailability and effectiveness of some products, like green tea extracts, were possible and would change the face of the industry.

Read more...
 
Big Pharma Could Take Notice of Nuvilex Inc.

As broad development of its proprietary live-cell encapsulation platform delivery system progresses, it is possible that “Big Pharma” takes notice of Nuvilex Inc. (OTCQB – NVLX).

Read more...
 
<< Start < Prev 31 32 33 34 35 36 37 38 39 40 Next > End >>

Page 33 of 40